259 related articles for article (PubMed ID: 8434456)
1. Liver cirrhosis in rheumatoid arthritis patients treated with long-term methotrexate.
Minocha A; Dean HA; Pittsley RA
Vet Hum Toxicol; 1993 Feb; 35(1):45-8. PubMed ID: 8434456
[TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
Lindsay K; Fraser AD; Layton A; Goodfield M; Gruss H; Gough A
Rheumatology (Oxford); 2009 May; 48(5):569-72. PubMed ID: 19273538
[TBL] [Abstract][Full Text] [Related]
3. Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis.
Clegg DO; Furst DE; Tolman KG; Pogue R
J Rheumatol; 1989 Aug; 16(8):1123-6. PubMed ID: 2585411
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis.
Kent PD; Luthra HS; Michet C
J Rheumatol; 2004 Sep; 31(9):1727-31. PubMed ID: 15338491
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages.
Carneiro SC; Cássia FF; Lamy F; Chagas VL; Ramos-e-Silva M
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):25-9. PubMed ID: 18181969
[TBL] [Abstract][Full Text] [Related]
6. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate.
Rau R; Karger T; Herborn G; Frenzel H
J Rheumatol; 1989 Apr; 16(4):489-93. PubMed ID: 2473207
[TBL] [Abstract][Full Text] [Related]
7. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis.
Ideguchi H; Ohno S; Ishigatsubo Y
J Clin Rheumatol; 2007 Apr; 13(2):73-8. PubMed ID: 17414533
[TBL] [Abstract][Full Text] [Related]
8. Hepatic fibrosis with the use of methotrexate for juvenile rheumatoid arthritis.
Keim D; Ragsdale C; Heidelberger K; Sullivan D
J Rheumatol; 1990 Jun; 17(6):846-8. PubMed ID: 2388211
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis.
Fathi NH; Mitros F; Hoffman J; Straniero N; Labreque D; Koehnke R; Furst DE
J Rheumatol; 2002 Oct; 29(10):2092-8. PubMed ID: 12375317
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate: the emerging drug of choice for serious rheumatoid arthritis.
Salach RH; Cash JM
Clin Ther; 1994; 16(6):912-22; discussion 911. PubMed ID: 7697687
[TBL] [Abstract][Full Text] [Related]
11. Liver biopsies from psoriatics related to methotrexate therapy. 2. Findings before and after methotexate therapy in 88 patients. A blind study.
Nyfors A; Poulsen H
Acta Pathol Microbiol Scand A; 1976 May; 84(3):262-70. PubMed ID: 1274591
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.
Prodanovich S; Ma F; Taylor JR; Pezon C; Fasihi T; Kirsner RS
J Am Acad Dermatol; 2005 Feb; 52(2):262-7. PubMed ID: 15692471
[TBL] [Abstract][Full Text] [Related]
13. [Blood cell concentration of methotrexate in long-term therapy of inflammatory rheumatic diseases].
Leeb B; Dunky A; Ogris E; Wohanka A; Schenk G; Fischer M; Tausch G; Eberl R
Acta Med Austriaca; 1988; 15(5):140-4. PubMed ID: 3146207
[TBL] [Abstract][Full Text] [Related]
14. [Rheumatoid arthritis, methothrexate, and pulmonary fibrosis: which evidences?].
Schaller D; Nendaz M; Gabay C
Rev Med Suisse; 2010 Mar; 6(240):547-8, 550, 552-4. PubMed ID: 20408459
[TBL] [Abstract][Full Text] [Related]
15. Effects on fibrogenesis markers of rheumatoid arthritis therapy with methotrexate.
Biasi D; Bambara LM; Carletto A; Casaril M; Capra F; Caramaschi P; Corrocher R
J Rheumatol; 1996 Mar; 23(3):453-4. PubMed ID: 8832981
[TBL] [Abstract][Full Text] [Related]
16. The effect of long-term methotrexate therapy on hepatic fibrosis in rheumatoid arthritis.
Bjorkman DJ; Boschert M; Tolman KG; Clegg DO; Ward JR
Arthritis Rheum; 1993 Dec; 36(12):1697-701. PubMed ID: 8250989
[TBL] [Abstract][Full Text] [Related]
17. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
18. Monitoring patients on methotrexate: hepatic fibrosis not seen in patients with normal serum assays of aminoterminal peptide of type III procollagen.
Maurice PD; Maddox AJ; Green CA; Tatnall F; Schofield JK; Stott DJ
Br J Dermatol; 2005 Mar; 152(3):451-8. PubMed ID: 15787813
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis.
Shergy WJ; Polisson RP; Caldwell DS; Rice JR; Pisetsky DS; Allen NB
Am J Med; 1988 Dec; 85(6):771-4. PubMed ID: 3195601
[TBL] [Abstract][Full Text] [Related]
20. Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate.
Usman AR; Yunus MB
J Rheumatol; 1996 Jun; 23(6):1095-7. PubMed ID: 8782146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]